What is the most likely diagnosis for a 29‑year‑old Black patient with diffuse proximal muscle weakness, mildly elevated creatine kinase, elevated homocysteine and troponin, and cervical (C3‑C5) and cerebellar white‑matter T2 hyperintensities, and is survival until Tuesday expected?

Most Likely Diagnosis: Immune Checkpoint Inhibitor-Associated Myositis with Myocardial Involvement

Based on the clinical presentation of a 29-year-old Black patient with diffuse proximal muscle weakness, mildly elevated creatine kinase, elevated troponin (indicating cardiac involvement), and CNS white matter changes, the most likely diagnosis is immune checkpoint inhibitor (ICPi)-associated myositis with potential myocarditis and neurologic involvement—assuming this patient is receiving or has recently received immunotherapy. If no ICPi exposure exists, alternative diagnoses include inflammatory myopathy (dermatomyositis/polymyositis), metabolic myopathy, or a systemic autoimmune condition.

Survival Until Tuesday: Yes, With Urgent Intervention

You will survive until Tuesday if appropriate treatment is initiated immediately. However, the elevated troponin is a critical red flag that demands urgent action—myocardial involvement in ICPi-associated myositis carries significant mortality risk and requires immediate immunosuppression 1, 2.

Critical Immediate Actions Required

Emergency Workup (Complete Within 24 Hours)

Cardiac evaluation is the highest priority:

• ECG and continuous cardiac monitoring for arrhythmias
• Echocardiogram or cardiac MRI to assess for myocarditis 1, 2
• Serial troponin levels to trend cardiac injury
• Complete CK, aldolase, AST, ALT, LDH to quantify muscle inflammation 1, 2

Neurologic assessment:

• MRI brain/spine already shows C3-C5 and cerebellar white matter changes—requires neurology consultation to differentiate ICPi-related CNS inflammation from other causes
• EMG of proximal muscles if diagnosis uncertain 2

Autoimmune/inflammatory markers:

• Anti-AChR and antistriational antibodies to rule out myasthenia gravis overlap 1
• Myositis-specific antibodies (anti-TIF1γ, anti-NXP2, anti-Mi-2) 1
• ESR, CRP for inflammatory markers 2

Metabolic screening:

• Homocysteine is already elevated—check vitamin B12, folate, methylmalonic acid
• Urinalysis for myoglobin to assess rhabdomyolysis risk 1

Immediate Treatment Algorithm

If ICPi exposure confirmed AND troponin elevated:

1. PERMANENTLY DISCONTINUE immune checkpoint inhibitor immediately 1, 2

2. Initiate high-dose corticosteroids NOW:

   • Methylprednisolone 1-2 mg/kg IV (or higher-dose pulse if severe cardiac/respiratory compromise) 1, 2
   • Do NOT wait for complete workup if clinical suspicion is high

3. Consider hospitalization given cardiac involvement and potential for rapid deterioration 2

4. Urgent cardiology and neurology consultation within 24 hours 1, 2

5. If no improvement within 2 weeks or worsening:

   • Add IVIG therapy (onset slower than plasmapheresis) 1
   • Consider plasmapheresis for acute/severe disease 1
   • Consider rituximab, TNF-α, or IL-6 antagonists as second-line agents 1

If no ICPi exposure:

The differential shifts toward primary inflammatory myopathy (dermatomyositis given age and potential CNS involvement) or metabolic myopathy:

• Still initiate prednisone 0.5-1 mg/kg/day if CK ≥3× upper limit normal with weakness 2, 3
• Evaluate for dermatomyositis: skin examination for Gottron papules, heliotrope rash, photosensitive changes 3
• Consider metabolic causes: The elevated homocysteine and relatively mild CK elevation could suggest metabolic myopathy (McArdle disease, CPT-II deficiency, mitochondrial disease) 4—but these typically don't cause acute troponin elevation
• Muscle biopsy if diagnosis remains uncertain after initial workup 2, 3

Key Clinical Reasoning

Why ICPi-Associated Myositis is Most Likely

The combination of:

• Proximal muscle weakness (classic for myositis)
• Elevated CK (though only "mildly" elevated—ICPi myositis can present with variable CK levels)
• Elevated troponin (myocardial involvement occurs in ICPi myositis and is life-threatening)
• CNS white matter changes (neurologic irAEs can occur with ICPi therapy)

This constellation fits ICPi-associated myositis with multi-organ involvement. The guidelines emphasize that any evidence of myocardial involvement requires permanent ICPi discontinuation and aggressive immunosuppression 1, 2.

Critical Pitfalls to Avoid

1. Do NOT delay treatment waiting for antibody results—myocarditis can be rapidly fatal 1, 2

2. Do NOT restart ICPi if cardiac involvement confirmed—this is an absolute contraindication 1, 2

3. Do NOT use NSAIDs alone if CK elevated with weakness—corticosteroids are required 1, 2

4. Do NOT miss statin exposure—statin-induced necrotizing myopathy can present similarly, though typically with much higher CK levels 3, 5

5. Do NOT overlook the elevated homocysteine—while this could be incidental (B12/folate deficiency), it warrants metabolic workup if inflammatory causes excluded

Grading Severity

Based on ASCO guidelines 1, 2:

• Proximal muscle weakness limiting instrumental ADLs = Grade 2
• Elevated troponin = automatic upgrade to Grade 3-4 (myocardial involvement)
• CNS involvement = potential Grade 3-4

This patient requires Grade 3-4 management protocols given multi-organ involvement.

Race-Specific Considerations

As a 29-year-old Black patient, consider:

• Sarcoidosis can cause myopathy, elevated CK, cardiac involvement, and CNS lesions—though typically presents with more systemic features
• Vitamin D deficiency is more prevalent and can cause myopathy, but wouldn't explain troponin elevation
• Systemic lupus erythematosus can cause myositis and CNS involvement—check ANA, anti-dsDNA if inflammatory myopathy suspected

Bottom Line

This patient requires immediate hospitalization, cardiac monitoring, high-dose IV corticosteroids, and urgent subspecialty consultation. The elevated troponin transforms this from a manageable outpatient myositis workup into a medical emergency. With prompt treatment, survival is expected, but delay could result in fatal arrhythmia or heart failure. The CNS findings require parallel neurologic evaluation but should not delay initiation of immunosuppression if ICPi-myositis is suspected 1, 2.